Alexandre Morel1, Josette Brière2, Laurence Lamant3, Michaël Loschi4, Corinne Haioun5, Richard Delarue1, Olivier Tournilhac6, Emmanuel Bachy7, Anne Sonet8, Sandy Amorim9, Camille Laurent3, Philippe Gaulard10, Hervé Tilly4, David Sibon11. 1. Hematology Department, Necker University Hospital, Greater Paris University Hospitals (AP-HP), Paris Descartes University-Sorbonne Paris Cité, Imagine Institute, Paris, France. 2. Pathology Department, Necker University Hospital, AP-HP, Paris Descartes University-Sorbonne Paris Cité, Imagine Institute, Paris, France. 3. Pathology Department, Institut Universitaire Du Cancer-Oncopole, Purpan University Hospital, Paul-Sabatier University, Toulouse, France. 4. Hematology Department, Henri-Becquerel Cancer Center, Rouen, France. 5. Hematology Department, Henri-Mondor University Hospital, AP-HP, Paris-Est University, Créteil, France. 6. Hematology Department, Estaing University Hospital, Auvergne University, Clermont-Ferrand, France. 7. Hospices Civils de Lyon, Université Claude-Bernard de Lyon, Hematology Department, Pierre-Bénite, France. 8. Université Catholique de Louvain, CHU UCL Namur, Department of Hematology, Yvoir, Belgium. 9. Onco-Hematology Department, Saint-Louis University Hospital, AP-HP, Paris Diderot University-Sorbonne Paris Cité, Paris, France. 10. Pathology Department, Henri-Mondor University Hospital, AP-HP, Paris-Est University, Créteil, France. 11. Hematology Department, Necker University Hospital, Greater Paris University Hospitals (AP-HP), Paris Descartes University-Sorbonne Paris Cité, Imagine Institute, Paris, France. Electronic address: david.sibon@aphp.fr.
Abstract
BACKGROUND: Long-term outcomes of adults with first-relapsed/refractory (R/R) systemic anaplastic large-cell lymphoma (ALCL) are not definitively established and should be evaluated. PATIENTS AND METHODS: We previously published the long-term outcomes of adults with ALCL initially treated with polychemotherapy in LYmphoma Study Association (LYSA) prospective clinical trials conducted during the pre-brentuximab vedotin era. Herein, we report the long-term outcomes of those patients after the first-relapsed/refractory (R/R) events. RESULTS: Among the 138 (64 (anaplastic lymphoma kinase (ALK(+)) and 74 ALK(-) ALCL) adults initially treated in clinical trials, 40 (14 ALK(+) and 26 ALK(-)) first-R/R ALCL patients and their long-term outcomes were analysed. Median follow-up from the first-R/R events was 12.5 years. For ALK(+) and ALK(-) patients, respectively, median [range] findings were as follows: age at first-R/R event: 35 [19-76] and 61 [34-81] years; time between inclusion in first-line clinical trials and first-R/R events was 6 [1.5-34] and 11.1 [1-67] months (P = 0.36); with median (95% confidence interval) progression-free survival after the first-R/R events: 3.8 (0.7-14.8) and 5.3 (2.4-8.4) months (P = 0.39); and overall survival: 13.6 (0.7-89) and 8.1 (3.3-25) months (P = 0.96). ALCL was the main cause of death. CONCLUSION: Most adults with first-R/R ALCL have poor outcomes, with no significant differences between patients with ALK(+) or ALK(-) disease. These results could be used as reference for the evaluation of new drugs to treat R/R ALCL.
BACKGROUND: Long-term outcomes of adults with first-relapsed/refractory (R/R) systemic anaplastic large-cell lymphoma (ALCL) are not definitively established and should be evaluated. PATIENTS AND METHODS: We previously published the long-term outcomes of adults with ALCL initially treated with polychemotherapy in LYmphoma Study Association (LYSA) prospective clinical trials conducted during the pre-brentuximab vedotin era. Herein, we report the long-term outcomes of those patients after the first-relapsed/refractory (R/R) events. RESULTS: Among the 138 (64 (anaplastic lymphoma kinase (ALK(+)) and 74 ALK(-) ALCL) adults initially treated in clinical trials, 40 (14 ALK(+) and 26 ALK(-)) first-R/R ALCL patients and their long-term outcomes were analysed. Median follow-up from the first-R/R events was 12.5 years. For ALK(+) and ALK(-) patients, respectively, median [range] findings were as follows: age at first-R/R event: 35 [19-76] and 61 [34-81] years; time between inclusion in first-line clinical trials and first-R/R events was 6 [1.5-34] and 11.1 [1-67] months (P = 0.36); with median (95% confidence interval) progression-free survival after the first-R/R events: 3.8 (0.7-14.8) and 5.3 (2.4-8.4) months (P = 0.39); and overall survival: 13.6 (0.7-89) and 8.1 (3.3-25) months (P = 0.96). ALCL was the main cause of death. CONCLUSION: Most adults with first-R/R ALCL have poor outcomes, with no significant differences between patients with ALK(+) or ALK(-) disease. These results could be used as reference for the evaluation of new drugs to treat R/R ALCL.
Authors: Jing Shen; Shaoying Li; L Jeffrey Medeiros; Pei Lin; Sa A Wang; Guilin Tang; C Cameron Yin; M James You; Joseph D Khoury; Swaminathan P Iyer; Roberto N Miranda; Jie Xu Journal: Mod Pathol Date: 2019-08-05 Impact factor: 7.842
Authors: Eva M Donato; Miguel Fernández-Zarzoso; Jose Antonio Hueso; Javier de la Rubia Journal: Onco Targets Ther Date: 2018-08-06 Impact factor: 4.147
Authors: Cosimo Lobello; Boris Tichy; Vojtech Bystry; Lenka Radova; Daniel Filip; Marek Mraz; Ivonne-Aidee Montes-Mojarro; Nina Prokoph; Hugo Larose; Huan-Chang Liang; Geeta G Sharma; Luca Mologni; David Belada; Katerina Kamaradova; Falko Fend; Carlo Gambacorti-Passerini; Olaf Merkel; Suzanne D Turner; Andrea Janikova; Sarka Pospisilova Journal: Leukemia Date: 2020-11-27 Impact factor: 11.528